JRCT ID: jRCTs031180259
Registered date:14/03/2019
Tolvaptan Intervention study and Genetic mutation of Autosomal Dominant Polycystic Kidney Disease
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | ADPKD |
| Date of first enrollment | 01/04/2019 |
| Target sample size | 10 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | Tolvaptan treatment |
Outcome(s)
| Primary Outcome | The Increase Rate of Total Kidney Volume |
|---|---|
| Secondary Outcome | The Decrease rate of estimated Glomerular Filtration Rate |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | ADPKD patients without genetic mutation of disease gene(PKD1, PKD2) |
| Exclude criteria | ADPKD patients with genetic mutation of disease gene(PKD1,PKD2) |
Related Information
| Primary Sponsor | Horie Shigeo |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Chemical Dojin Co., Ltd |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Satoru Muto |
| Address | 3-1-3, Hongo 3 cho-me, Bunkyo-ku, Tokyo Tokyo Japan 113-8431 |
| Telephone | +81-3-3813-3111 |
| s-muto@juntendo.ac.jp | |
| Affiliation | Juntendo University Hospital |
| Scientific contact | |
| Name | Shigeo Horie |
| Address | 3-1-3, Hongo 3 cho-me, Bunkyo-ku, Tokyo Tokyo Japan 113-8431 |
| Telephone | +81-3-3813-3111 |
| shorie@juntendo.ac.jp | |
| Affiliation | Juntendo University Hospital |